Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.

doi:10.3389/pore.2021.592997

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.

Pathology oncology research : POR - 1 Jan 2021

Huang Richard S P, Severson Eric, Haberberger James, Duncan Daniel L, Hemmerich Amanda, Edgerly Claire, Ferguson N Lynn, Frampton Garrett, Owens Clarence, Williams Erik, Elvin Julia, Vergilio Jo-Anne, Killian Jonathan Keith, Lin Douglas, Morley Samantha, McEwan Deborah, Holmes Oliver, Danziger Natalie, Cohen Michael B, Sathyan Pratheesh, McGregor Kimberly, Reddy Prasanth, Venstrom Jeffrey, Anhorn Rachel, Alexander Brian, Brown Charlotte, Ross Jeffrey S, Ramkissoon Shakti H

Abstract excerpt

Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion diagnostic testing. We examined 9450 NSCLC real-world patient samples that underwent both CGP and programmed death-ligand 1 (PD-L1) IHC to understand the biomarker landscape in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Genomics

Share to Immunohistochemistry

Share to Immunotherapy

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34257540
DOI: 10.3389/pore.2021.592997
PMCID: PMC8262230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.PMID 34257540Read ↗

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Prognostic and predictive biomarkers in non-small cell lung carcinoma.Semantic proximity Read ↗

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.Semantic proximity Read ↗

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.Semantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.Semantic proximity Read ↗

Precision medicine in non-small cell lung cancer: Current applications and future directions.Semantic proximity Read ↗

Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database.Semantic proximity Read ↗

[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].Semantic proximity Read ↗

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.